Pharmacodynamic monitoring by residual NFAT-regulated gene expression in stable pediatric liver transplant recipients

Pediatric Transplantation

Volumn 16, Issue 2, 2012, Pages 187-194

  Billing, Heiko ^a   Breil, Thomas ^a   Schmidt, Jan ^b   Tönshoff, Burkhard ^a   Schmitt, Claus ^a   Giese, Thomas ^b   Engelmann, Guido ^a,c  

^a Department of Pediatrics   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

child; liver transplantation; NFAT; pharmacodynamic monitoring

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LYMPHOKINE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EXPOSURE; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; PRESCHOOL CHILD; RECURRENT DISEASE; SCHOOL CHILD; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 84857511123     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2012.01660.x     Document Type: Article

References (31)

1. Kim J-S, Groteluschen R, Mueller T, et al., Pediatric transplantation: The Hamburg experience. Transplantation 2005: 79: 1206-1209. (Pubitemid 40664025)
2. Calne RY, White DJ, Thiru S, et al., Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978: 2: 1323-1327. (Pubitemid 9078430)
3. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A,. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989: 2: 1000-1004. (Pubitemid 19257914)
4. Starzl TE, Koep LJ, Schroter GP, Halgrimson CG, Porter KA, Weil R,. Liver replacement for pediatric patients. Pediatrics 1979: 63: 825-829. (Pubitemid 9160869)
5. Starzl TE, Murase N, Abu-Elmagd K, et al., Tolerogenic immunosuppression for organ transplantation. Lancet 2003: 361: 1502-1510. (Pubitemid 36566340)
6. Chow J, Golan Y,. Vaccination of solid-organ transplantation candidates. Clin Infect Dis 2009: 49: 1550-1556.
7. Opelz G, Dohler B,. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008: 86: 371-376.
8. Hübscher S,. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl 2009: 15 (Suppl 2): S19-S24.
9. Guido M, Burra P,. De novo autoimmune hepatitis after liver transplantation. Semin Liver Dis 2011: 31: 71-81.
10. Furlan V, Lykavieris P, Maubert MA, Habes D, Debray D,. Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation. Transplant Proc 2009: 41: 3333-3334.
11. Marin JG, Levine M, Ensom MHH,. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 2006: 28: 637-642. (Pubitemid 44564062)
12. Clipstone NA, Crabtree GR,. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992: 357: 695-697.
13. Hermann-Kleiter N, Baier G,. NFAT pulls the strings during CD4+ T helper cell effector functions. Blood 2010: 115: 2989-2997.
14. Sommerer C, Schnitzler P, Meuer S, Zeier M, Giese T,. Pharmacodynamic monitoring of cyclosporin a reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. Ther Drug Monit 2011: 33: 694-698.
15. Herden U, Kromminga A, Hagel C, et al., Monitoring of nuclear factor of activated T-cell-regulated gene expression in de novo and long-term liver transplant recipients treated with cyclosporine a. Ther Drug Monit 2011: 33: 185-191.
16. Giese T, Zeier M, Schemmer P, et al., Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: A novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004: 77: 339-344. (Pubitemid 38209728)
17. Billing H, Giese T, Sommerer C, et al., Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplant 2010: 14: 844-851.
18. Sommerer C, Konstandin M, Dengler T, et al., Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006: 82: 1280-1285. (Pubitemid 44832909)
19. Sommerer C, Zeier M, Czock D, Schnitzler P, Meuer S, Giese T,. Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011: 33: 373-379.
20. Konstandin MH, Sommerer C, Doesch A, et al., Pharmacodynamic cyclosporine A-monitoring: Relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007: 20: 1036-1043. (Pubitemid 350043847)
21. Giese T, Sommerer C, Zeier M, Meuer S,. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol 2009: 132: 305-311.
22. Demetris AJ, Batts KP, Dhillon AP, et al., Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997: 25: 658-663. (Pubitemid 27106450)
23. Hubscher SG,. What is the long-term outcome of the liver allograft? J Hepatol 2011: 55: 702-717.
24. Evans HM, Kelly DA, McKiernan PJ, Hübscher S,. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006: 43: 1109-1117. (Pubitemid 43724635)
25. Schwartz GJ, Furth SL,. Glomerular filtration rate measurement and estimation in chronic kidney disease. Pediatr Nephrol 2007: 22: 1839-1848. (Pubitemid 47506223)
26. Shepherd RW, Turmelle Y, Nadler M, et al., Risk factors for rejection and infection in pediatric liver transplantation. Am J Transplant 2008: 8: 396-403.
27. Sommerer C, Hartschuh W, Enk A, Meuer S, Zeier M, Giese T,. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008: 22: 549-554.
28. Sommerer C, Zeier M, Meuer S, Giese T,. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010: 89: 1417-1423.
29. Halloran PF, Helms LM, Kung L, Noujaim J,. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999: 68: 1356-1361.
30. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE,. Once- versus twice-daily tacrolimus: Are the formulations truly equivalent? Drugs 2011: 71: 1561-1577.
31. Nourse JP, Jones K, Gandhi MK,. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am J Transplant 2011: 11: 888-895.